SBIR/STTR Research Award
ANTI-C. DIFFICILE HUMAN MONOCLONALS FOR IMMUNOTHERAPY
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MAPP BIOPHARMACEUTICAL, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- M9V9QTHR1H28
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Clostridium difficile associated disease (CDAD) is an important cause of morbidity in hospital and nursing home patients, and is being increasingly recognized as an important cause of mortality. The objective of t
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Novel Cost-Effective Multispecific Therapeutic for Dengue
- Development of highly potent human monoclonal for RSV immunoprophylaxis
- Marburg Virus Prophylactic Medical Countermeasure
- Development of highly potent human monoclonal for RSV immuno-prophylaxis
- Post-exposure immunotherapy for ricin exposure
Research funding history
29 SBIR/STTR records share this UEI (2004–2025). Reported award amounts total $27,737,822. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense
Contractor profile
Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.
Agency intelligence
Department of Health and Human Services
NAICS intelligence
This classification comes from the contractor profile, not from the SBIR award record.